[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam pulls TV ads after FDA crackdown, while also dosing the first patient in a new trial. Investors are watching the company's next moves as the stock price fluctuates with mixed news and sentiment.

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics.
Alnylam Pharmaceuticals, Inc. uses the ticker $ALNY for trading. Listed in the Stocks and category within the Healthcare sectors.

Insights #

Alnylam Pharmaceuticals, Inc. (ALNY) trading volume is up XXXXXX% from the previous week.
Alnylam Pharmaceuticals, Inc. (ALNY) social dominance is up XXXXXX% from the previous week.
Alnylam Pharmaceuticals, Inc. (ALNY) posts created is up XX% from the previous week.

Price: $XXXXXX #

Price 24-Hour Time-Series Raw Data
The stock price is experiencing volatility due to mixed news. Positive data from the HELIOS-B study and strong sales are countered by the ad pull and negative sentiment on X, leading to a balanced outlook. The 24-hour price change is 0.1%, while the 7-day change is 0.9%, and the 30-day change is -1.17%.

24-Hour	7-Day	30-Day
XXXX%	XXXX%	XXXX%

1-Year High: $XXXXXX on 2025-09-09
1-Year Low: $XXXXXX on 2025-04-08

AltRank: XXXXX #

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Alnylam Pharmaceuticals, Inc. (ALNY) is currently AltRank #1,719 based on combined combined social and market metrics Daily Average: XXX
1 Week: XXX -XX
1 Month: XXXXX +1,072
6 Months: XXXXX +1,407
1 Year: XXXXX +1,382
1-Year High: XXXXX on 2025-06-26
1-Year Low: X on 2025-03-22

Galaxy Score: XXXXX #

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
1 Week: XX -X
1 Month: XX -X
6 Months: XX +9
1 Year: XX -XX
1-Year High: XX on 2025-02-19
1-Year Low: XX on 2025-06-26

Engagements: XXXXXX #

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXXX
Daily Average: XXXXXX
1 Week: XXXXXX -XX%
1 Month: XXXXXXX -XX%
6 Months: XXXXXXXXX +24%
1 Year: XXXXXXXXX -XX%
1-Year High: XXXXXXX on 2025-03-21
1-Year Low: XXXXX on 2025-10-12

Social Network	X	News
Engagements	XXXXXX	XX

Mentions: XXX #

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXX
1 Week: XX -XX%
1 Month: XXX -XX%
6 Months: XXXXX +9.40%
1 Year: XXXXX -X%
1-Year High: XXX on 2024-11-28
1-Year Low: XX on 2025-01-27

Social Network	X	News
Mentions	XXX	X

Creators: XX #

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Alnylam Pharmaceuticals, Inc. (ALNY) in the last XX hours which is up XX% from XX in the previous XX hours Daily Average: XXX
1 Week: XX -XX%
1 Month: XXX -XX%
6 Months: XXXXX +83%
1 Year: XXXXX +72%
1-Year High: XXX on 2025-06-28
1-Year Low: XX on 2025-01-27

The most influential creators that mention Alnylam Pharmaceuticals, Inc. in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@Quantumup1	X	XXXXX	X	XXXXX
@GeneInvesting	X	XXXXXX	X	XXXXX
@MacroSkokie	X	XXXXX	X	XXX
@Biobeats99	X	XXX	XX	XXX
@boogeymantradez	X	XXXXX	X	XXX
@IBDinvestors	X	XXXXXXX	X	XXX
@mikeycolombia33	X	XXXXX	XX	XXX
@JimmyTrustFund	X	XXX	X	XXX
@RNAiAnalyst	X	XXXXXX	X	XXX
@MarcJacksonLA	XX	XXXXX	X	XX

Sentiment: XX% #

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
1 Week: XX% +3%
1 Month: XX% +16%
6 Months: XX% +24%
1 Year: XX% +10%
1-Year High: XXX% on 2025-07-29
1-Year Low: XX% on 2025-05-28

Most Supportive Themes

Positive Data from HELIOS-B Study: (35%) New data from the HELIOS-B Phase X study demonstrates lower rates of gastrointestinal events in ATTR-CM patients treated with Vutrisiran, supporting its role as a first-line therapy.
Amvuttra Sales and Revenue Guidance: (20%) Alnylam reported strong Amvuttra sales and raised its 2025 revenue guidance, indicating positive financial performance.
First Patient Dosed in ZENITH Trial: (15%) Alnylam announced the first patient dosed in the ZENITH Global Phase X cardiovascular outcomes trial of Zilebesiran, signaling progress in its clinical pipeline.

Most Critical Themes

FDA Crackdown and Ad Pull: (10%) Alnylam pulled TV ads following a crackdown on drug industry advertising, which may raise concerns.
Negative Sentiment on X: (20%) A large percentage of X posts express negative sentiment, with many users expressing concerns about the company.

Network engagement breakdown:

Network	Positive	%	Neutral	%	Negative	%
X	XXXXX	XX%	XXXXXX	XX%	XXX	X%
News	X	X%	X	X%	X	X%

Total	XXXXX	XX%	XXXXXX	XX%	XXX	X%

Social Dominance: XXXXX% #

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: XXXXX%
1 Week: XXXXX% +0.019%
1 Month: XXXXX% +0.019%
6 Months: XXXXX% -XXXXXX%
1 Year: XXXXX% -XXXXX%
1-Year High: XXXXX% on 2024-11-06
1-Year Low: XXXXXX% on 2025-07-29

Market Dominance: XXXXX% #

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: X%
1-Year High: XXXX% on 2024-10-16
1-Year Low: XXXXX% on 2025-03-25

Market Cap: $XXXXXXXXXXXXXX #

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXXX
1 Week: $XXXXXXXXXXXXXX +$2.10%
1 Month: $XXXXXXXXXXXXXX +$0.74%
6 Months: $XXXXXXXXXXXXXX +$103%
1 Year: $XXXXXXXXXXXXXX +$69%
1-Year High: $XXXXXXXXXXXXXX on 2025-09-09
1-Year Low: $XXXXXXXXXXXXXX on 2025-04-08

Top assets mentioned In the posts about Alnylam Pharmaceuticals, Inc. in the last XX hours

Alnylam Pharmaceuticals, Inc. (ALNY) Pfizer, Inc. (PFE) BridgeBio Pharma, Inc. Common Stock (BBIO) Johnson & Johnson (JNJ) Intellia Therapeutics, Inc (NTLA) Johnson & Johnson (JNJ) BioMarin Pharmaceutical, Inc. (BMRN) Merck & Co., Inc. (MRK) Ionis Pharmaceuticals, Inc. Common Stock (IONS)

Top topics mentioned In the posts about Alnylam Pharmaceuticals, Inc. in the last XX hours

stocks healthcare, $pfe, investment, stocks technology, $bbio, stocks financial services, johnson johnson, coins defi, $ntla, $jnj, coins dao, stocks, telegram, $bmrn, $mrk, $ions, $mdgl, stocks industrials, stocks consumer cyclical, regeneron pharmaceuticals inc, $qure, $adhcon, $arwr, stocks banks, bloomberg, stocks consumer defensive, $adhc0015, $orcl, $insm, illumina inc, $ilmn, $abbv, $imvt, $nvo, stocks basic materials, $adhcfda, $adhc, $adhc0016, $dnli, $incy, coins solana ecosystem, bank of america, $xbi, stocks energy, $knsa, $rvmd, $amgn, $ge, stocks defense, vertex protocol, vertex pharma, $ajg, $wfc, $ptgx, $cien, $bwxt, $tln, $mirm, has been, $sln, coins base ecosystem, superrarebears, dough, $srrk, $regn, align technology inc, $algn, $vrt, stocks utilities, crowdstrike, $nvda, $avgo, blackrock, $prqr, $blue, $kymr, $300m, $nvs, albemarle corp, $alb, allegion plc, $mp, $ecl, $ferg, market cap, $argx, $atyr, alt aptoslaunch token, $alab, $4342k, $263m, $xene, $492m, $350m, sofi technologies, hc, $22m, $cask, $168k, $prgo